US-based life sciences company LabCorp’s Covance Drug Development business has formed an immunology and immunotoxicology (I&I) unit aimed at global biologic drug development needs.

The new unit will combine Covance’s expertise in flow cytometry, immunoassays and cell-based assay operations with scientific expertise in immunotoxicology study design, direction and operation.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Covance expects that this integration will provide a more comprehensive offering for large-molecule drugs.

Covance CEO John Ratliff said: “With the formation of this team, we continue to demonstrate Covance’s commitment to strengthening our biologics solutions with key investments in scientific staff, technology and facilities.

“Integrating our scientific and operational know-how into a seamless group allows us to deliver even richer scientific insights and faster cycle times for clients’ biologic programmes, which helps our clients bring cutting-edge new drugs to patients faster.”

“Our growing I&I team is capitalising on the global experience of our established facilities in the US, Germany and the UK to deliver comprehensive support for large-molecule development.”

Covance offers support and advice on various stages of biologics development such as pre-clinical assessment, regulatory submission and clinical sample analysis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Through the new unit, the company will also provide access to bioanalysis to be used in regulatory submission, and to Phase I clinical research units for first-in-human and first-in-patient studies.

The I&I experts at the unit will benefit from the expertise of Covance’s clinical development and commercialisation, translational biomarker and immuno-oncology teams, and LabCorp’s scientific and technical capabilities.

According to senior vice-president of Covance Early Development, Steve Street, the unit will also work on new assay development and validation.

Street added: “Our growing I&I team is capitalising on the global experience of our established facilities in the US, Germany and the UK to deliver comprehensive support for large-molecule development, from innovative testing methods to insightful data analysis and interpretation.